Intratumoural injection of ARL67156 into ATG5-deficient (ATG5KD) tumour cells significantly enhanced lymphocyte recruitment into irradiated ATG5KD CT26 cancers (Figure 5), commensurate with the improved growth-inhibitory action of irradiation on such tumours. Here, ATG5 is linked to neoplasm.